Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Blood (2024) 144 (Supplement 1): 7832.

https://doi.org/10.1182/blood-2024-204276

Published: 2024

Journal Articles

Trajectories of Patient-Reported Outcomes after Idecabtagene Vicleucel Vs. Ciltacabtagene Autoleucel CAR T-Cell Therapy Among Patients with Relapsed/Refractory Multiple Myeloma in Standard of Care

Blood (2024) 144 (Supplement 1): 7842.

https://doi.org/10.1182/blood-2024-208668

Published: 2024

Journal Articles

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2024-209164

Published: 2024

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Blood (2024) 144 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2024-206353

Published: 2024

Journal Articles

Single-Cell Analysis of CAR-T Cell Products Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Reveals Factors That Influence Clinical Outcomes

Jerald Noble, Xiaofei Song, Meghan Menges, Julieta Abraham-Miranda, Salvatore Corallo, Gabriel De Avila, Omar Puglianini, Hien Liu, Melissa Alsina, Taiga Nishihori, Kenneth H. Shain, Rachid Baz, Brandon Blue, Ariel Grajales-Cruz, Doris K. Hansen, Reginald Atkins, Frederick L. Locke, Ciara Louise Freeman

Blood (2024) 144 (Supplement 1): 7173.

https://doi.org/10.1182/blood-2024-208709

Published: 2024

Journal Articles

Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Filip Ionescu, Shrinjaya B Thapa, Parth C Patel, Dimitrios Drekolias, Ariosto Siqueira Silva, Praneeth R Sudalagunta, Phaedra Agius, Brandon Blue, Doris K. Hansen, Omar Castaneda, Hien Liu, Jose L. Ochoa-Bayona, Ciara Louise Freeman, Frederick Locke, Taiga Nishihori, Melissa Alsina, Kenneth H. Shain, Rachid Baz, Ariel Grajales-Cruz

Blood (2024) 144 (Supplement 1): 4740.

https://doi.org/10.1182/blood-2024-210069

Published: 2024

Journal Articles

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 896.

https://doi.org/10.1182/blood-2024-197929

Published: 2024

Journal Articles

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Blood (2024) 144 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2024-210263

Published: 2024

Journal Articles

Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Blood (2024) 144 (Supplement 1): 5168.

https://doi.org/10.1182/blood-2024-211739

Published: 2024

Journal Articles

Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Blood (2024) 144 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2024-208529

Published: 2024

Journal Articles

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 4826.

https://doi.org/10.1182/blood-2024-202363

Published: 2024

Journal Articles

Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Fnu Amisha, Ziad Abuhelwa, Wenyi Fan, Doris K. Hansen, Omar Castaneda, Ciara Louise Freeman, Hien Liu, Frederick Locke, Taiga Nishihori, Ariel Grajales-Cruz, Brandon Blue, Kenneth H. Shain, Melissa Alsina, Rachid Baz

Blood (2024) 144 (Supplement 1): 2004.

https://doi.org/10.1182/blood-2024-211822

Published: 2024

Journal Articles

Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy

Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, Gabriel De Avila, Doris K. Hansen, Ariel F. Grajales-Cruz, Brandon Blue, Omar Castaneda, Hien Liu, Ciara Louise Freeman, Taiga Nishihori, Frederick Locke, Kenneth H. Shain, Rachid Baz, Melissa Alsina

Blood (2024) 144 (Supplement 1): 4692.

https://doi.org/10.1182/blood-2024-204270

Published: 2024

Journal Articles

Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3784.

https://doi.org/10.1182/blood-2024-204232

Published: 2024

Journal Articles

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Blood (2024) 144 (Supplement 1): 4921.

https://doi.org/10.1182/blood-2024-199289

Published: 2024

Journal Articles

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2023) 142 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2023-174506

Published: 2023

Journal Articles

Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines

Ciara Louise L. Freeman, Julieta Abraham Miranda, Meghan Menges, Jerald Noble, Hien Liu, Salvatore Corallo, Albert J Ribickas, Constanza Savid-Frontera, Gabriel De Avila, Omar Castaneda, Jose L. Ochoa-Bayona, Rachid Baz, Doris K. Hansen, Melissa Alsina, Kenneth H. Shain, Taiga Nishihori, Reginald Atkins, Frederick L. Locke

Blood (2023) 142 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2023-187539

Published: 2023

Journal Articles

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2023-185117

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazaryan, Jose L. Ochoa-Bayona, Hien Liu, Michael D. Jain, Michael Nieder, Claudio Anasetti, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan, Hany Elmariah

Blood (2023) 142 (Supplement 1): 390.

https://doi.org/10.1182/blood-2023-186738

Published: 2023

Journal Articles

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Hany Elmariah, Jongphil Kim, Asmita Mishra, Rawan Faramand, Lia Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Jose L. Ochoa-Bayona, Michael Nieder, Nicholas Figura, Timothy J Robinson, Taiga Nishihori, Claudio Anasetti, Joseph A. Pidala, Nelli Bejanyan

Blood (2023) 142 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2023-187473

Published: 2023

NARROW

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Trajectories of Patient-Reported Outcomes after Idecabtagene Vicleucel Vs. Ciltacabtagene Autoleucel CAR T-Cell Therapy Among Patients with Relapsed/Refractory Multiple Myeloma in Standard of Care

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Single-Cell Analysis of CAR-T Cell Products Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Reveals Factors That Influence Clinical Outcomes

Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy

Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only